ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger
This article was originally published in The Gray Sheet
Executive Summary
ViroLogic's new HIV replication assay will help drive conversion of the resistance testing market from genotype to phenotype-based tests, the firm believes